The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Beard Growth Essence
Beard Growth Essence · MYRISTOYL PENTAPEPTIDE-4 .5 mg/g; BIOTINOYL TRIPEPTIDE-1 .5 mg/g · Solution · Topical · Guangzhou Kanglixin Medical Biotechnology Co., Ltd.
NDC 84854-0001-01 · 50 g in 1 BOTTLE · OTC MONOGRAPH DRUG · View full market →
Medicare Part D
Medicare Part D does not cover over-the-counter drugs — by law it pays only for products requiring a prescription.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Regulatory
- Application
- 505G(a)(3)
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Beard Growth Essence (Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Guangzhou Kanglixin Medical Biotechnology Co., Ltd. | MYRISTOYL PENTAPEPTIDE-4 .5 mg/g; BIOTINOYL TRIPEPTIDE-1 .5 mg/g | Jul 22, 2026 | Sep 2, 2026 |
| Guangzhou Kanglixin Medical Biotechnology Co., Ltd. | BIOTINOYL TRIPEPTIDE-1 .5 mg/g; MYRISTOYL PENTAPEPTIDE-4 .5 mg/g | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Beard Growth Essence — NDC 84854-0001-01," retrieved September 3, 2026, https://drugdashboards.com/drug/84854000101.
Free to cite with attribution — see how the data is put together.